Topiramate In Pregnancy May Raise Child Development Risks

What was studied

This paper was a systematic review, which means the authors gathered and assessed results from earlier studies rather than doing a new experiment. They looked for studies on children exposed to topiramate during pregnancy in persons with epilepsy of childbearing potential.

The review searched major medical databases and included 14 studies published in English from 2014 to 2024. Across those studies, the number of children exposed to topiramate ranged from 2 to 1,000. The main comparison groups were children of pregnant people without epilepsy and without antiseizure medicine use, or children exposed to antiseizure medicines other than topiramate.

What they found

Overall, the review found mixed evidence suggesting an association between prenatal exposure to topiramate and neurodevelopmental disorders such as autism spectrum disorder, intellectual disability, and ADHD. Seven studies found a relationship, three did not find an increased risk, and four were inconclusive.

The increased risk seemed mainly to be seen when topiramate was compared with no antiseizure medicine use. In many studies, the risk with topiramate was similar to lamotrigine and lower than valproate. The authors concluded that topiramate prescribing requires caution in persons with epilepsy of childbearing potential and that topiramate use during pregnancy warrants special attention to the neurodevelopment of the child.

Limits of the evidence

This review cannot prove that topiramate directly causes neurodevelopmental disorders. It summarizes observational studies, which can be affected by other factors.

Many studies had very small numbers of topiramate-exposed children, and the methods differed across studies. The results were not fully consistent, and some studies were inconclusive or poor quality. The abstract also does not give detailed information about dose effects, timing during pregnancy, or how strongly risk changed.

For families and caregivers

For families, this review suggests there may be an increased risk of later neurodevelopmental disorders after exposure to topiramate during pregnancy, especially compared with no antiseizure medicine exposure. But the evidence is mixed: the risk may be similar to some other medicines like lamotrigine and lower than with valproate.

This matters because medicine choices in pregnancy need careful consideration. The review supports careful medicine planning before and during pregnancy and paying attention to a child's developmental milestones if there was prenatal topiramate exposure, without assuming that problems will happen.

What to watch next

Stronger evidence would come from larger studies that carefully compare medicine dose, timing in pregnancy, and long-term child neurodevelopment.

Terms in this summary

systematic review

A study that collects and evaluates results from many earlier studies using a planned method.

neurodevelopmental disorders

Conditions that affect how the brain develops, which can change learning, behavior, attention, or social skills.

autism spectrum disorder

A developmental condition that affects communication, social interaction, and behavior.

intellectual disability

A condition involving limits in learning, reasoning, and everyday functioning.

ADHD

Attention-deficit/hyperactivity disorder, a condition that can cause problems with attention, activity level, and impulse control.

antiseizure medicine

A medicine used to help prevent or control seizures.

lamotrigine

An antiseizure medicine often used to treat epilepsy.

valproate

An antiseizure medicine associated with higher risk than topiramate in this review.